BioLineRx Ltd.

Foreign Filer Report • Sep 25, 2019

BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors false

������� �� ��� ��"�	2 380
BIOLINE RX LTD
Corporation no: 513398750	9253
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	25/09/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-099052	Time of broadcast: 13:49 13:46:46

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors

6-K_AGI-134_250919_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
2019-02-077061
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2019
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: normank@biolinerx.com 1
Israel